Olympus Corporation recalled 1,070 EVIS EXERA II bronchoscopes on September 11, 2025. The recall addresses safety concerns regarding their use with laser and high-frequency therapy equipment. Healthcare providers should stop using these devices immediately.
Additional IFU updates to provide further clarification on safe and effective use of bronchoscopes when used in conjunction with laser, argon plasma coagulation, and high-frequency therapy equipment.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Olympus Corporation of the Americas or your healthcare provider for instructions
The recall involves the EVIS EXERA II Bronchovideoscope Olympus BF Type P180. A total of 1,070 units are recalled in the U.S. and 2,180 units internationally. The devices were distributed nationwide.
The recall stems from additional instructions for use updates. These updates clarify the safe and effective use of bronchoscopes when combined with laser, argon plasma coagulation, and high-frequency therapy equipment.
No specific incidents, injuries, or deaths have been reported in connection with this recall. However, the risk associated with improper use necessitates immediate action.
Stop using the affected bronchoscopes immediately. Patients and healthcare providers should follow the recall instructions provided by Olympus Corporation.
For further instructions, contact Olympus Corporation of the Americas. Visit their website or call customer service for assistance.
Get notified about recalls in categories you care about.
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.